APOA5 and metabolic dysfunction-associated steatotic liver disease: Hepatic apoA5 protein expression in NAFLD mice were significantly elevated compared with control mice, and metformin similarly dose-dependently reduced hepatic apoA5 expressions of these ob/ob mice (all p < 0.05) (Figure 1D).